Class Action Lawsuit Against PepGen Inc. Affects Investors: Deadline Approaches
On July 1, 2025, Levi & Korsinsky, LLP, a distinguished law firm well-known for representing investors, announced a class action lawsuit aimed at PepGen Inc., a company listed on NASDAQ under the ticker PEPG. This legal action was initiated to recover losses suffered by investors who allegedly fell victim to securities fraud committed by the company. The time frame for the alleged malfeasance extends from March 7, 2024, to March 3, 2025. As these events unfold, investors now have a crucial opportunity to join the lawsuit before the deadline of August 8, 2025.
The lawsuit claims that PepGen Inc. and its defendants made misleading statements regarding their lead product candidate PGN-EDO51. Investors were reportedly led to believe that the drug was both effective and safe, yet the complaint outlines concerns over its actual efficacy and safety profile. Additionally, claims arise that the second phase of their clinical trial, known as the CONNECT2 study, was not only dangerous but also deficient in meeting U.S. Food and Drug Administration (FDA) approval standards.
It is alleged that these misrepresentations significantly overstated the potential clinical, regulatory, and market success for PGN-EDO51, while leading to a situation where the CONNECT2 study could potentially be halted altogether. As a result, the public declarations made by PepGen Inc. could have been materially false and misleading at all relevant times, thereby affecting investor confidence and financial outcomes.
For those who experienced losses in their investments with PepGen Inc. during the specified timeline, the law firm urges them to take action by opting into the lawsuit by the approaching deadline. Importantly, individuals wishing to join the class action do not necessarily need to serve as a lead plaintiff. The legal team from Levi & Korsinsky ensures that the process entails no out-of-pocket costs for involved class members.
Anyone interested in participating can find further information through the law firm's official channels. Interested parties are encouraged to either follow the link provided or contact Attorney Joseph E. Levi directly via email or phone for assistance.
Levi & Korsinsky, LLP has garnered a strong reputation over the past 20 years for effectively representing shareholders and recovering significant amounts in various cases. The firm boasts an impressive track record in handling complex securities litigation, and they have consistently been ranked among the top securities litigation firms in the United States for several consecutive years. This solid foundation in investor protection offers confidence to those considering participating in the class action against PepGen Inc.
With over 70 professionals dedicated to their clients, the firm stands ready to assist investors in navigating this legal landscape, ensuring they can claim their rightful compensation for any losses endured.
In summary, PepGen Inc. investors who believe they have been affected by the actions described in the class action lawsuit have a limited window to join forces with Levi & Korsinsky’s dedicated legal team. Participants in this lawsuit may not only find solace in shared grievances but might also be entitled to compensation for their losses without incurring any fees upfront. The impending deadline of August 8, 2025, beckons prompt action for anyone wishing to recoup their investments in PepGen Inc.
Background of the Case
The lawsuit claims that PepGen Inc. and its defendants made misleading statements regarding their lead product candidate PGN-EDO51. Investors were reportedly led to believe that the drug was both effective and safe, yet the complaint outlines concerns over its actual efficacy and safety profile. Additionally, claims arise that the second phase of their clinical trial, known as the CONNECT2 study, was not only dangerous but also deficient in meeting U.S. Food and Drug Administration (FDA) approval standards.
It is alleged that these misrepresentations significantly overstated the potential clinical, regulatory, and market success for PGN-EDO51, while leading to a situation where the CONNECT2 study could potentially be halted altogether. As a result, the public declarations made by PepGen Inc. could have been materially false and misleading at all relevant times, thereby affecting investor confidence and financial outcomes.
Getting Involved in the Class Action
For those who experienced losses in their investments with PepGen Inc. during the specified timeline, the law firm urges them to take action by opting into the lawsuit by the approaching deadline. Importantly, individuals wishing to join the class action do not necessarily need to serve as a lead plaintiff. The legal team from Levi & Korsinsky ensures that the process entails no out-of-pocket costs for involved class members.
Anyone interested in participating can find further information through the law firm's official channels. Interested parties are encouraged to either follow the link provided or contact Attorney Joseph E. Levi directly via email or phone for assistance.
Why Choose Levi & Korsinsky?
Levi & Korsinsky, LLP has garnered a strong reputation over the past 20 years for effectively representing shareholders and recovering significant amounts in various cases. The firm boasts an impressive track record in handling complex securities litigation, and they have consistently been ranked among the top securities litigation firms in the United States for several consecutive years. This solid foundation in investor protection offers confidence to those considering participating in the class action against PepGen Inc.
With over 70 professionals dedicated to their clients, the firm stands ready to assist investors in navigating this legal landscape, ensuring they can claim their rightful compensation for any losses endured.
Conclusion
In summary, PepGen Inc. investors who believe they have been affected by the actions described in the class action lawsuit have a limited window to join forces with Levi & Korsinsky’s dedicated legal team. Participants in this lawsuit may not only find solace in shared grievances but might also be entitled to compensation for their losses without incurring any fees upfront. The impending deadline of August 8, 2025, beckons prompt action for anyone wishing to recoup their investments in PepGen Inc.
Topics Financial Services & Investing）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.